Literature DB >> 11550998

Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk?

N Marx1, P Libby, J Plutzky.   

Abstract

Peroxisome proliferator-activated receptors (PPARs) are nuclear transcription factors that regulate gene expression in response to activation by specific ligands including insulin sensitizing thiazolidinedione and lipid-lowering fibrates. Recent work has identified PPARalpha and PPARgamma expression in vascular cells and established a role for these receptors in the regulation of genes relevant to atherogenesis. The following review will focus on the role of PPAR activation in the vasculature and discuss the potential clinical implications of these findings.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11550998     DOI: 10.1177/174182670100800404

Source DB:  PubMed          Journal:  J Cardiovasc Risk        ISSN: 1350-6277


  9 in total

1.  PREMATURE VASCULAR SENESCENCE IN METABOLIC SYNDROME: COULD IT BE PREVENTED AND REVERSED BY A SELENORGANIC ANTIOXIDANT AND PEROXYNITRITE SCAVENGER EBSELEN?

Authors:  Jun Chen; Hyeong-Cheon Park; Susann Patschan; Sergey V Brodsky; Olga Gealikman; Mei-Chuan Kuo; Houwei Li; Francesco Addabbo; Fung Zhang; Alberto Nasjletti; Steven S Gross; Michael S Goligorsky
Journal:  Drug Discov Today Ther Strateg       Date:  2007

Review 2.  Lipaemia, inflammation and atherosclerosis: novel opportunities in the understanding and treatment of atherosclerosis.

Authors:  Antonie J H H M van Oostrom; Jeroen van Wijk; Manuel Castro Cabezas
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.

Authors:  Nikolaus Marx; Bettina Kehrle; Klaus Kohlhammer; Miriam Grüb; Wolfgang Koenig; Vinzenz Hombach; Peter Libby; Jorge Plutzky
Journal:  Circ Res       Date:  2002-04-05       Impact factor: 17.367

4.  Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.

Authors:  Haiyan Xu; Glenn T Barnes; Qing Yang; Guo Tan; Daseng Yang; Chieh J Chou; Jason Sole; Andrew Nichols; Jeffrey S Ross; Louis A Tartaglia; Hong Chen
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

Review 5.  Metabolic and additional vascular effects of thiazolidinediones.

Authors:  Fabrice M A C Martens; Frank L J Visseren; Jacinthe Lemay; Eelco J P de Koning; Ton J Rabelink
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Inhibition of MMP-9 expression by PPARgamma activators in human bronchial epithelial cells.

Authors:  M Hetzel; D Walcher; M Grüb; H Bach; V Hombach; N Marx
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

7.  A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial.

Authors:  Olivier F Bertrand; Paul Poirier; Josep Rodés-Cabau; Stéphane Rinfret; Lawrence Title; Vladimir Dzavik; Madhu Natarajan; Juan Angel; Nuria Batalla; Natalie Alméras; Olivier Costerousse; Robert De Larochellière; Louis Roy; Jean-Pierre Després
Journal:  Can J Cardiol       Date:  2009-09       Impact factor: 5.223

Review 8.  Human adipose dynamics and metabolic health.

Authors:  Bin Feng; Tracy Zhang; Haiyan Xu
Journal:  Ann N Y Acad Sci       Date:  2013-01-14       Impact factor: 5.691

9.  Obesity-related upregulation of monocyte chemotactic factors in adipocytes: involvement of nuclear factor-kappaB and c-Jun NH2-terminal kinase pathways.

Authors:  Ping Jiao; Qiu Chen; Suketu Shah; Jing Du; Bo Tao; Iphigenia Tzameli; Weiqun Yan; Haiyan Xu
Journal:  Diabetes       Date:  2008-10-03       Impact factor: 9.461

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.